CHEPLAPHARM Registration GmbH
CHEPLAPHARM Registration GmbH, based in Lörrach (Germany), was founded in 2023 as an affiliate of the globally active CHEPLAPHARM group and as a direct subsidiary of CHEPLAPHARM Schweiz GmbH. The group’s headquarters, CHEPLAPHARM Arzneimittel GmbH, are based in Greifswald (Germany).
CHEPLAPHARM Registration was incorporated to hold the EU marketing authorizations of the products owned by CHEPLAPHARM Switzerland and is located in walking distance to the Swiss Border in Lörrach (Germany).
Who is CHEPLAPHARM Arzneimittel GmbH?
CHEPLAPHARM Arzneimittel GmbH is an internationally recognized and leading company in the field of specialty pharmaceuticals. The company was founded in Germany in 1998. It got its name in reference to one of its first products in the range, the diuretic Cheplaren.
In 2003, CHEPLAPHARM Arzneimittel GmbH was acquired by the Braun family and transformed into a responsible and fast-growing family-owned company that has evolved into a leading global pharmaceutical company over the past two decades. CHEPLAPHARM Arzneimittel GmbH is represented in more than 145 countries worldwide with more than 3,200 marketing authorizations. The company relies on a large and diverse network of more than 125 contract manufacturers (CMOs) or active ingredient suppliers and more than 100 distribution partners.
CHEPLAPHARM Arzneimittel GmbH is already represented worldwide through its extensive network of production and distribution partners. With the establishment of CHEPLAPHARM Registration GmbH, the company can further advance its global strategy.
Its solid and long-standing experience in the pharmaceutical industry as well as in mergers and acquisitions, combined with convincing results, makes CHEPLAPHARM Arzneimittel GmbH a preferred and trusted partner for pharmaceutical companies.
At the same time, the company ensures that millions of patients worldwide can rely on a continuous, high-quality supply of their trusted medicines in compliance with all applicable quality and safety standards.
Maintaining and ensuring the continued availability of these long established medicines is a top priority for CHEPLAPHARM Arzneimittel GmbH.